121 related articles for article (PubMed ID: 6771006)
1. Activation of Ftorafue [R,S-1-(tetrahydro-2-furanyl)-5-fluorouracil] to 5-fluorouracil and gamma-butyrolactone.
Au JL; Sadée W
Cancer Res; 1980 Aug; 40(8 Pt 1):2814-9. PubMed ID: 6771006
[No Abstract] [Full Text] [Related]
2. Metabolic activation of R,S-1-(tetrahydro-2-furanyl)-5-fluorouracil (ftorafur) to 5-fluorouracil by soluble enzymes.
El Sayed YM; Sadée W
Cancer Res; 1983 Sep; 43(9):4039-44. PubMed ID: 6409396
[TBL] [Abstract][Full Text] [Related]
3. Metabolic activation of ftorafur [R,S-1-(tetrahydro-2-furanyl)-5-fluorouracil]: the microsomal oxidative pathway.
El Sayed YM; Sadée W
Biochem Pharmacol; 1982 Sep; 31(18):3006-8. PubMed ID: 6814451
[No Abstract] [Full Text] [Related]
4. Stereoselective metabolism of ftorafur (R,S-1-(tetrahydro-2-furanyl)-5-fluorouracil).
Au JL; Sadée W
Cancer Chemother Pharmacol; 1981; 7(1):55-9. PubMed ID: 6804104
[No Abstract] [Full Text] [Related]
5. Cytochrome P-450-dependent oxidative cleavage of 1-(tetrahydro-2-furanyl)-5-fluorouracil to 5-fluorouracil.
Kawata S; Minami Y; Tarui S; Marunaka T; Okamoto M; Yamano T
Jpn J Pharmacol; 1984 Sep; 36(1):43-9. PubMed ID: 6438379
[TBL] [Abstract][Full Text] [Related]
6. Disposition and metabolism of 1-(tetrahydro-2-furanyl)-5-fluorouracil (ftorafur) in humans.
Benvenuto JA; Lu K; Hall SW; Benjamin RS; Loo TL
Cancer Res; 1978 Nov; 38(11 Pt 1):3867-70. PubMed ID: 359130
[TBL] [Abstract][Full Text] [Related]
7. Formation pathways of gamma-butyrolactone from the furan ring of tegafur during its conversion to 5-fluorouracil.
Yamamiya I; Yoshisue K; Matsushima E; Nagayama S
Drug Metab Dispos; 2010 Aug; 38(8):1267-76. PubMed ID: 20463005
[TBL] [Abstract][Full Text] [Related]
8. Hydroxylated metabolies of R,S-1-(tetrahydro-2-furanyl)-5-fluorouracil (Ftorafur) in rats and rabbits.
Wu AT; Au JL; Sadée W
Cancer Res; 1978 Jan; 38(1):210-4. PubMed ID: 338145
[TBL] [Abstract][Full Text] [Related]
9. Metabolism of 1,3-bis(tetrahydro-2-furanyl)-5-fluorouracil in mice.
Fujimoto S; Ishigami H; Minami T; Miyazaki M; Itoh K; Kimura K
J Natl Cancer Inst; 1979 Aug; 63(2):465-8. PubMed ID: 379401
[TBL] [Abstract][Full Text] [Related]
10. [Participation of non-specific rat liver microsome oxidases in destruction of Nl-furanidylpyrimidines].
Meĭren DV; Urbanovich EL; Sniedze TN; Khagi KhB; Gilev AP
Biull Eksp Biol Med; 1977 Feb; 83(2):162-4. PubMed ID: 15682
[TBL] [Abstract][Full Text] [Related]
11. Involvement of microsomal cytochrome P450 and cytosolic thymidine phosphorylase in 5-fluorouracil formation from tegafur in human liver.
Komatsu T; Yamazaki H; Shimada N; Nagayama S; Kawaguchi Y; Nakajima M; Yokoi T
Clin Cancer Res; 2001 Mar; 7(3):675-81. PubMed ID: 11297264
[TBL] [Abstract][Full Text] [Related]
12. Enzymatic formation of 5-fluorouracil from 1-(tetrahydro-2-furanyl)- 5-fluorouracil (tegafur) in human tumor tissues.
Kono A; Hara Y; Matsushima Y
Chem Pharm Bull (Tokyo); 1981 May; 29(5):1486-8. PubMed ID: 6794918
[No Abstract] [Full Text] [Related]
13. The pharmacology of ftorafur (R, S-1-(tetrahydro-2-furanyl)-5-fluorouracil.
Au JL; Sadée W
Recent Results Cancer Res; 1981; 76():100-14. PubMed ID: 6785848
[No Abstract] [Full Text] [Related]
14. Pharmacokinetics and metabolism of ftorafur in man.
Au JL; Wu AT; Friedman MA; Sadée W
Cancer Treat Rep; 1979 Mar; 63(3):343-50. PubMed ID: 371796
[No Abstract] [Full Text] [Related]
15. Identification of metabolites of 1-(tetrahydro-2-furanyl)-5-fluorouracil (FT-207) formed in vitro by rat liver microsomes.
Marunaka T; Minami Y; Umeno Y; Yasuda A; Sato T; Fujii S
Chem Pharm Bull (Tokyo); 1980 Jun; 28(6):1795-80. PubMed ID: 6773678
[No Abstract] [Full Text] [Related]
16. Metabolism, antitumor activity, and acute toxicity of 5-fluoro-1,3-bis(tetrahydro-2-furanyl)-2,4-pyrimidinedione by oral administration to animals.
Fujii S; Nakamura Y; Takeda S; Morita K; Sato T; Marunaka T; Kawaguchi Y; Unemi N
Gan; 1980 Feb; 71(1):30-44. PubMed ID: 6769737
[TBL] [Abstract][Full Text] [Related]
17. Studies to increase the antitumor activity of 1-(tetrahydro-2-furanyl)-5-fluorouracil and its metabolic aspects by combined administration with L-cysteine.
Kawabata N; Sugiyama S; Kuwamura T; Satoh T; Kitagawa H
Jpn J Pharmacol; 1983 Aug; 33(4):735-47. PubMed ID: 6415326
[TBL] [Abstract][Full Text] [Related]
18. [Metabolism of tegafur in partial hepatectomized rats].
Maehara Y; Anai H; Kusumoto H; Miyamoto K; Fukuchi K; Sugimachi K
Gan To Kagaku Ryoho; 1986 Oct; 13(10):3078-80. PubMed ID: 3094460
[No Abstract] [Full Text] [Related]
19. Studies of antitumor agents. 1. Resolution of racemic 1-(tetrahydro-2-furanyl)-k-fluorouracil into the R and S isomers and examination of the biological activities of the isomers.
Yasumoto M; Moriyama A; Unemi N; Hashimoto S; Suzue T
J Med Chem; 1977 Dec; 20(12):1592-4. PubMed ID: 338900
[TBL] [Abstract][Full Text] [Related]
20. Species variation in the enantioselective metabolism of tegafur to 5-fluorouracil among rats, dogs and monkeys.
Yamamiya I; Yoshisue K; Ishii Y; Yamada H; Yoshida K
J Pharm Pharmacol; 2014 Dec; 66(12):1686-97. PubMed ID: 25117829
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
